IP Library › Granted Patent US 12,370,308
Granted Patent B2
US 12,370,308 · App. 17/504,568 · Granted Jul 29, 2025

Determination of adjustments to fluid delivery settings

Inventors: Neha J. Parikh (West Hills, CA); Anirban Roy (Agoura Hills, CA); Benyamin Grosman (Winnetka, CA); Patrick E. Weydt (Moorpark, CA); Louis J. Lintereur (Boise, ID); Di Wu (Palo Alto, CA); Francine R. Kaufman (Los Angeles, CA); Scott W. Lee (Redlands, CA)
Assignee: MEDTRONIC MINIMED, INC.
A61M5/1723A61M5/172G16H20/17A61M2005/14208A61M2205/50A61M2205/502A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,370,308
App. No.
17/504,568
Granted
Jul 29, 2025
Kind
B2
Abstract

Disclosed herein are techniques related to determination of adjustments to fluid delivery settings. In some embodiments, the techniques may involve accessing insulin delivery data for a user of an insulin delivery device. The insulin delivery data may be indicative of an amount of insulin delivered by the insulin delivery device to the user during a time period. The techniques may also involve analyzing the insulin delivery data to generate an updated insulin sensitivity factor (ISF) value. The techniques may further involve generating, based on the updated ISF value, a recommendation to adjust an ISF value of the insulin delivery device. Additionally, the techniques may involve causing adjustment of the ISF value to the updated ISF value in accordance with the recommendation.

Claims (66)

1. A processor-implemented method comprising:

accessing insulin delivery data for a user of an insulin delivery device, wherein the insulin delivery data was collected during a closed-loop mode of the insulin delivery device and is indicative of a total amount of insulin delivered by the insulin delivery device to the user during a time period;

generating an updated insulin sensitivity factor (ISF) value based on an average total daily dose (TDD) of insulin determined using the insulin delivery data collected during the closed-loop mode;

generating, based on the updated ISF value, a recommendation to adjust an ISF value for a manual mode of the insulin delivery device, wherein the ISF value for the manual mode is separate from an ISF value for the closed-loop mode; and

causing the insulin delivery device to deliver insulin in the manual mode based on the updated ISF value in accordance with the recommendation.

2. The processor-implemented method of claim 1 , wherein the processor-implemented method is performed by a computing device in data communication with the insulin delivery device.

3. The processor-implemented method of claim 1 , further comprising communicating the recommendation to the insulin delivery device to adjust the ISF value on the insulin delivery device.

4. The processor-implemented method of claim 1 , further comprising controlling operation of the insulin delivery device in accordance with the updated ISF value.

5. The processor-implemented method of claim 1 , wherein the total amount of insulin delivered to the user during the time period comprises the average total daily dose (TDD) of insulin for the user.

6. The processor-implemented method of claim 1 , wherein:

the ISF value is updated in accordance with an expression

ISF

=

X

Average

⁢

⁢

TDD

;

ISF is expressed in units of mg/dL/Unit;

X is expressed in units of mg/dL/day and relates to an insulin regimen of the insulin delivery device; and

Average TDD is expressed in units of Units/day.

7. The processor-implemented method of claim 1 , wherein the processor-implemented method is performed by the insulin delivery device.

8. The processor-implemented method of claim 1 , wherein generating the recommendation includes generating, based on the updated ISF value being different from a current ISF value by at least a threshold amount, the recommendation to adjust the ISF value for the manual mode of the insulin delivery device.

9. A system comprising:

one or more processors; and

one or more processor-readable storage media operatively coupled with the one or more processors, the one or more processor-readable storage media storing executable instructions which, when executed by the one or more processors, cause performance of operations comprising:

accessing insulin delivery data for a user of an insulin delivery device, wherein the insulin delivery data was collected during a closed-loop mode of the insulin delivery device and is indicative of a total amount of insulin delivered by the insulin delivery device to the user during a time period;

generating, based on an average total daily dose (Average TDD) of insulin determined using the insulin delivery data collected during the closed-loop mode, an updated insulin sensitivity factor (ISF) value in accordance with an expression

ISF

=

X

Average

⁢

⁢

TDD

;

 wherein X relates to an insulin regimen of the insulin delivery device;

generating, based on the updated ISF value, a recommendation to adjust an ISF value for a manual mode of the insulin delivery device, wherein the ISF value for the manual mode is separate from an ISF value for the closed-loop mode; and

causing the insulin delivery device to deliver insulin in the manual mode based on the updated ISF value in accordance with the recommendation.

10. The system of claim 9 , wherein the operations are performed by a computing device in data communication with the insulin delivery device, and wherein the computing device comprises the one or more processors and the one or more processor-readable storage media.

11. The system of claim 9 , wherein the operations further comprise communicating the recommendation to the insulin delivery device to adjust the ISF value on the insulin delivery device.

12. The system of claim 9 , wherein the one or more processor-readable storage media further store instructions which, when executed by the one or more processors, cause performance of: controlling operation of the insulin delivery device in accordance with the updated ISF value.

13. The system of claim 9 , wherein the total amount of insulin delivered to the user during the time period comprises the average total daily dose (TDD) of insulin for the user.

14. The system of claim 9 , wherein the operations are performed by the insulin delivery device, and wherein the insulin delivery device comprises the one or more processors and the one or more processor-readable storage media.

15. One or more non-transitory processor-readable storage media storing executable instructions which, when executed by one or more processors, cause performance of operations comprising:

accessing insulin delivery data for a user of an insulin delivery device, wherein the insulin delivery data was collected during a closed-loop mode of the insulin delivery device and is indicative of a total amount of insulin delivered by the insulin delivery device to the user during a time period;

generating an updated ISF value based on an average total daily dose (TDD) of insulin determined using the insulin delivery data collected during the closed-loop mode;

generating, based on the updated ISF value, a recommendation to adjust an ISF value for a manual mode of the insulin delivery device, wherein the ISF value for the manual mode is different from an ISF value for the closed-loop mode; and

causing the insulin delivery device to deliver insulin in the manual mode based on the updated ISF value in accordance with the recommendation.

16. The one or more non-transitory processor-readable storage media of claim 15 , wherein the operations are performed by a computing device in data communication with the insulin delivery device.

17. The one or more non-transitory processor-readable storage media of claim 15 , wherein the operations further comprise communicating the recommendation to the insulin delivery device to adjust the ISF value on the insulin delivery device.

18. The one or more non-transitory processor-readable storage media of claim 15 , wherein the total amount of insulin delivered to the user during the time period comprises the average total daily dose (TDD) of insulin for the user.

19. The one or more non-transitory processor-readable storage media of claim 15 , wherein:

the ISF value is updated in accordance with an expression

ISF

=

X

Average

⁢

⁢

TDD

;

 and

X relates to an insulin regimen of the insulin delivery device.

20. The one or more non-transitory processor-readable storage media of claim 15 , wherein the operations are performed by the insulin delivery device.

Assignments (2)
SECURITY INTEREST Recorded Jan 16, 2026
From: MEDTRONIC MINIMED, INC.; COMPANION MEDICAL, INC.
To: CITIBANK, N.A.
Reel/Frame 074394/0237 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2021
From: PARIKH, NEHA J.; ROY, ANIRBAN; GROSMAN, BENYAMIN; WEYDT, PATRICK E.; LINTEREUR, LOUIS J.; WU, DI; KAUFMAN, FRANCINE R.; LEE, SCOTT W.
To: MEDTRONIC MINIMED, INC.
Reel/Frame 057831/0943 →
Continuity (2)
Continuation 15960495 · Apr 23, 2018
Related Publication 20220031946A1 · Feb 3, 2022
References Cited (214)
US 4562751A · Nason et al. · 1986 [cited by applicant]
US 4685903A · Cable et al. · 1987 [cited by applicant]
US 4755173A · Konopka et al. · 1988 [cited by applicant]
US 5080653A · Voss et al. · 1992 [cited by applicant]
US 5097122A · Colman et al. · 1992 [cited by applicant]
US 5391250A · Cheney, II et al. · 1995 [cited by applicant]
US 5485408A · Blomquist · 1996 [cited by applicant]
US 5505709A · Funderburk et al. · 1996 [cited by applicant]
US 5522803A · Teissen-Simony · 1996 [cited by applicant]
US 5665065A · Colman et al. · 1997 [cited by applicant]
US 5800420A · Gross et al. · 1998 [cited by applicant]
US 5807375A · Gross et al. · 1998 [cited by applicant]
US 5925021A · Castellano et al. · 1999 [cited by applicant]
US 5954643A · Antwerp et al. · 1999 [cited by applicant]
US 6017328A · Fischell et al. · 2000 [cited by applicant]
US 6088608A · Schulman et al. · 2000 [cited by applicant]
US 6119028A · Schulman et al. · 2000 [cited by applicant]
US 6186982B1 · Gross et al. · 2001 [cited by applicant]
US 6246992B1 · Brown · 2001 [cited by applicant]
US 6248067B1 · Causey, III et al. · 2001 [cited by applicant]
US 6248093B1 · Moberg · 2001 [cited by applicant]
US 6355021B1 · Nielsen et al. · 2002 [cited by applicant]
US 6379301B1 · Worthington et al. · 2002 [cited by applicant]
US 6485465B2 · Moberg et al. · 2002 [cited by applicant]
US 6544212B2 · Galley et al. · 2003 [cited by applicant]
US 6554798B1 · Mann et al. · 2003 [cited by applicant]
US 6558320B1 · Causey, III et al. · 2003 [cited by applicant]
US 6558351B1 · Steil et al. · 2003 [cited by applicant]
US 6589229B1 · Connelly et al. · 2003 [cited by applicant]
US 6591876B2 · Safabash · 2003 [cited by applicant]
US 6641533B2 · Causey, III et al. · 2003 [cited by applicant]
US 6659980B2 · Moberg et al. · 2003 [cited by applicant]
US 6736797B1 · Larsen et al. · 2004 [cited by applicant]
US 6740072B2 · Starkweather et al. · 2004 [cited by applicant]
US 6749587B2 · Flaherty · 2004 [cited by applicant]
US 6752787B1 · Causey, III et al. · 2004 [cited by applicant]
US 6766183B2 · Walsh et al. · 2004 [cited by applicant]
US 6801420B2 · Talbot et al. · 2004 [cited by applicant]
US 6804544B2 · Van Antwerp et al. · 2004 [cited by applicant]
US 6817990B2 · Yap et al. · 2004 [cited by applicant]
US 6827702B2 · Lebel et al. · 2004 [cited by applicant]
US 6932584B2 · Gray et al. · 2005 [cited by applicant]
US 7003336B2 · Holker et al. · 2006 [cited by applicant]
US 7029444B2 · Shin et al. · 2006 [cited by applicant]
US 7066909B1 · Peter et al. · 2006 [cited by applicant]
US 7137964B2 · Flaherty · 2006 [cited by applicant]
US 7303549B2 · Flaherty et al. · 2007 [cited by applicant]
US 7323142B2 · Pendo et al. · 2008 [cited by applicant]
US 7399277B2 · Saidara et al. · 2008 [cited by applicant]
US 7402153B2 · Steil et al. · 2008 [cited by applicant]
US 7442186B2 · Blomquist · 2008 [cited by applicant]
US 7602310B2 · Mann et al. · 2009 [cited by applicant]
US 7621893B2 · Moberg et al. · 2009 [cited by applicant]
US 7647237B2 · Malave et al. · 2010 [cited by applicant]
US 7699807B2 · Faust et al. · 2010 [cited by applicant]
US 7727148B2 · Talbot et al. · 2010 [cited by applicant]
US 7785313B2 · Mastrototaro · 2010 [cited by applicant]
US 7806886B2 · Kanderian, Jr. et al. · 2010 [cited by applicant]
US 7819843B2 · Mann et al. · 2010 [cited by applicant]
US 7828764B2 · Moberg et al. · 2010 [cited by applicant]
US 7879010B2 · Nunn et al. · 2011 [cited by applicant]
US 7890295B2 · Shin et al. · 2011 [cited by applicant]
US 7892206B2 · Moberg et al. · 2011 [cited by applicant]
US 7892748B2 · Norrild et al. · 2011 [cited by applicant]
US 7901394B2 · Ireland et al. · 2011 [cited by applicant]
US 7942844B2 · Moberg et al. · 2011 [cited by applicant]
US 7946985B2 · Mastrototaro et al. · 2011 [cited by applicant]
US 7955305B2 · Moberg et al. · 2011 [cited by applicant]
US 7963954B2 · Kavazov · 2011 [cited by applicant]
US 7977112B2 · Burke et al. · 2011 [cited by applicant]
US 7979259B2 · Brown · 2011 [cited by applicant]
US 7985330B2 · Wang et al. · 2011 [cited by applicant]
US 8024201B2 · Brown · 2011 [cited by applicant]
US 8100852B2 · Moberg et al. · 2012 [cited by applicant]
US 8114268B2 · Wang et al. · 2012 [cited by applicant]
US 8114269B2 · Cooper et al. · 2012 [cited by applicant]
US 8137314B2 · Mounce et al. · 2012 [cited by applicant]
US 8181849B2 · Bazargan et al. · 2012 [cited by applicant]
US 8182462B2 · Istoc et al. · 2012 [cited by applicant]
US 8192395B2 · Estes et al. · 2012 [cited by applicant]
US 8195265B2 · Goode, Jr. et al. · 2012 [cited by applicant]
US 8202250B2 · Stutz, Jr. · 2012 [cited by applicant]
US 8207859B2 · Enegren et al. · 2012 [cited by applicant]
US 8226615B2 · Bikovsky · 2012 [cited by applicant]
US 8257259B2 · Brauker et al. · 2012 [cited by applicant]
US 8267921B2 · Yodfat et al. · 2012 [cited by applicant]
US 8275437B2 · Brauker et al. · 2012 [cited by applicant]
US 8277415B2 · Mounce et al. · 2012 [cited by applicant]
US 8292849B2 · Bobroff et al. · 2012 [cited by applicant]
US 8298172B2 · Nielsen et al. · 2012 [cited by applicant]
US 8303572B2 · Adair et al. · 2012 [cited by applicant]
US 8305580B2 · Aasmul · 2012 [cited by applicant]
US 8308679B2 · Hanson et al. · 2012 [cited by applicant]
US 8313433B2 · Cohen et al. · 2012 [cited by applicant]
US 8318443B2 · Norrild et al. · 2012 [cited by applicant]
US 8323250B2 · Chong et al. · 2012 [cited by applicant]
US 8343092B2 · Rush et al. · 2013 [cited by applicant]
US 8352011B2 · Van Antwerp et al. · 2013 [cited by applicant]
US 8353829B2 · Say et al. · 2013 [cited by applicant]
US 8474332B2 · Bente, IV et al. · 2013 [cited by applicant]
US 8674288B2 · Hanson et al. · 2014 [cited by applicant]
US 9526834B2 · Keenan et al. · 2016 [cited by applicant]
US 9907909B2 · Finan et al. · 2018 [cited by applicant]
US 11147919B2 · Parikh et al. · 2021 [cited by applicant]
US 11158413B2 · Grosman et al. · 2021 [cited by applicant]
US 11367526B2 · Chiu et al. · 2022 [cited by applicant]
US 11986629B2 · Wu et al. · 2024 [cited by applicant]
US 12073932B2 · Grosman et al. · 2024 [cited by applicant]
US 20020193679A1 · Malave · 2002 [cited by examiner]
US 20070123819A1 · Mernoe et al. · 2007 [cited by applicant]
US 20080262745A1 · Polidori · 2008 [cited by applicant]
US 20080269714A1 · Mastrototaro · 2008 [cited by examiner]
US 20090036753A1 · King · 2009 [cited by examiner]
US 20090164239A1 · Hayter et al. · 2009 [cited by applicant]
US 20100160861A1 · Causey, III et al. · 2010 [cited by applicant]
US 20100249561A1 · Patek et al. · 2010 [cited by applicant]
US 20110130746A1 · Budiman · 2011 [cited by applicant]
US 20110208156A1 · Doyle, III et al. · 2011 [cited by applicant]
US 20130030358A1 · Yodfat · 2013 [cited by examiner]
US 20130190583A1 · Grosman et al. · 2013 [cited by applicant]
US 20130231642A1 · Doyle, III et al. · 2013 [cited by applicant]
US 20130338630A1 · Agrawal et al. · 2013 [cited by applicant]
US 20140066889A1 · Grosman et al. · 2014 [cited by applicant]
US 20140066892A1 · Keenan · 2014 [cited by examiner]
US 20140128705A1 · Mazlish · 2014 [cited by applicant]
US 20140200559A1 · Doyle, III et al. · 2014 [cited by applicant]
US 20140276554A1 · Finan et al. · 2014 [cited by applicant]
US 20140276555A1 · Morales · 2014 [cited by applicant]
US 20150057807A1 · Mastrototaro et al. · 2015 [cited by applicant]
US 20150352282A1 · Mazlish · 2015 [cited by examiner]
US 20160030339A1 · Muhlen-Bartmer et al. · 2016 [cited by applicant]
US 20160162662A1 · Monirabbasi · 2016 [cited by examiner]
US 20170056591A1 · Breton et al. · 2017 [cited by applicant]
US 20170143899A1 · Gondhalekar et al. · 2017 [cited by applicant]
US 20170189614A1 · Mazlish · 2017 [cited by examiner]
US 20170332952A1 · Desborough et al. · 2017 [cited by applicant]
US 20180020988A1 · Patek · 2018 [cited by applicant]
US 20180099092A1 · Roy · 2018 [cited by applicant]
US 20180174675A1 · Roy et al. · 2018 [cited by applicant]
US 20180200439A1 · Mazlish · 2018 [cited by examiner]
US 20180200441A1 · Desborough et al. · 2018 [cited by applicant]
US 20180286518A1 · Raju et al. · 2018 [cited by applicant]
US 20180296757A1 · Finan · 2018 [cited by examiner]
US 20190005195A1 · Peterson et al. · 2019 [cited by applicant]
US 20190258904A1 · Ma et al. · 2019 [cited by applicant]
US 20190336684A1 · O'Connor et al. · 2019 [cited by applicant]
US 20200093988A1 · Zhong et al. · 2020 [cited by applicant]
US 20200098463A1 · Arunachalam et al. · 2020 [cited by applicant]
US 20200098464A1 · Velado et al. · 2020 [cited by applicant]
US 20200098465A1 · Jiang et al. · 2020 [cited by applicant]
US 20200101221A1 · Lintereur et al. · 2020 [cited by applicant]
US 20200101224A1 · Lintereur et al. · 2020 [cited by applicant]
US 20200135311A1 · Mairs · 2020 [cited by applicant]
US 20200246543A1 · Sadeghzadeh et al. · 2020 [cited by applicant]
US 20200282141A1 · Rousson et al. · 2020 [cited by applicant]
US 20200342974A1 · Chen et al. · 2020 [cited by applicant]
US 20200390973A1 · Wu et al. · 2020 [cited by applicant]
US 20210100486A1 · Romero Ugalde et al. · 2021 [cited by applicant]
US 20220044785A1 · Grosman et al. · 2022 [cited by applicant]
US 20240261505A1 · Wu et al. · 2024 [cited by applicant]
US 20240371492A1 · Grosman et al. · 2024 [cited by applicant]
AU 2019260574A1 · 2020 [cited by applicant]
CA 3107454A1 · 2019 [cited by applicant]
CN 104520862A · 2015 [cited by applicant]
CN 104756116A · 2015 [cited by applicant]
CN 104769595A · 2015 [cited by applicant]
CN 112005310A · 2020 [cited by applicant]
CN 113646847A · 2021 [cited by applicant]
EP 3785276A1 · 2021 [cited by applicant]
EP 3935646A1 · 2022 [cited by applicant]
JP 2003079723A · 2003 [cited by applicant]
JP 2005508025A · 2005 [cited by applicant]
JP 2008545493A · 2008 [cited by applicant]
JP 2010523167A · 2010 [cited by applicant]
JP 2010532044A · 2010 [cited by applicant]
JP 2011523940A · 2011 [cited by applicant]
JP 2021522582A · 2021 [cited by applicant]
KR 20210004993A · 2021 [cited by applicant]
WO 2014035570A2 · 2014 [cited by applicant]
WO 2014035672A2 · 2014 [cited by applicant]
WO 2016133879A1 · 2016 [cited by applicant]
WO 2018033513A1 · 2018 [cited by applicant]
WO 2019209602A1 · 2019 [cited by applicant]
WO 2020214780A1 · 2020 [cited by applicant]
Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract. Dec. 2008;14(9):1095-101. doi: 10… [cited by examiner]
CN Office Action dated Oct. 12, 2023 in CN Application No. CN201980025847.6 with English translation. [cited by applicant]
Hughes, C., et al., Safety Supervision System Design and Implications for Continuous Subcutaneous Insulin Infusion (Csii) In TIDM, Ph.D. Dissertation, University of Virginia, 2011, 240 pages. [cited by applicant]
International Preliminary Report on Patentability dated Oct. 28, 2021, in PCT Application No. PCT/US2020/028461. [cited by applicant]
International Search Report and Written Opinion dated Jul. 9, 2020, in Application No. PCT/US2020/028461. [cited by applicant]
JP Office Action dated Mar. 14, 2023 in Application No. JP2020-559417 with English translation. [cited by applicant]
Kirchsteiger, H., et al., “Reduced Hypoglycemia Risk in Insulin Bolus Therapy Using Asymmetric Cost Functions,” Proceedings of the 7th Asian Control Conference, Aug. 2009, pp. 751-756. [cited by applicant]
U.S. Advisory Action dated Dec. 12, 2023 in U.S. Appl. No. 16/438,407. [cited by applicant]
U.S Advisory Action dated Jun. 20, 2023 in U.S. Appl. No. 16/438,407. [cited by applicant]
U.S Advisory Action dated Sep. 16, 2022 in U.S. Appl. No. 16/438,407. [cited by applicant]
U.S. Final Office Action dated Apr. 4, 2023 in U.S. Appl. No. 16/438,407. [cited by applicant]
U.S. Final Office Action dated Jul. 5, 2022 in U.S. Appl. No. 16/438,407. [cited by applicant]
U.S. Final Office Action dated Oct. 24, 2023 in U.S. Appl. No. 16/438,407. [cited by applicant]
U.S. Non-Final Office Action dated Dec. 23, 2022 in U.S. Appl. No. 16/438,407. [cited by applicant]
U.S. Non-Final Office Action dated Jan. 21, 2021, in U.S. Appl. No. 15/960,495. [cited by applicant]
U.S. Non-Final Office Action dated Jul. 19, 2023, in U.S. Appl. No. 16/438,407. [cited by applicant]
U.S. Non-Final Office Action dated Mar. 14, 2022 in U.S. Appl. No. 16/438,407. [cited by applicant]
U.S. Non-Final Office Action dated Mar. 31, 2021, in U.S. Appl. No. 16/386,104. [cited by applicant]
U.S. Non-Final Office Action dated Oct. 6, 2023, in U.S. Appl. No. 17/509,670. [cited by applicant]
Wang, Q et al., “Model Predictive Control for Type 1 Diabetes Based on Personalized Linear Time-Varying Subject Model Consisting of both Insulin and Meal Inputs: in Silica Evaluation”, American Control Conference, Jul. … [cited by applicant]
Zarkogianni, K., et al., “An Insulin Infusion Advisory System Based on Autotuning Nonlinear Model-Predictive Control,” IEEE Transactions on Biomedical Engineering, 2011, vol. 55 (9), pp. 2467-2477. [cited by applicant]
AU Office Action dated Oct. 31, 2023 in AU Application No. 2019260574 [MEDTP030]. [cited by applicant]
Lee, et al., “Thesis: Personalization and Enhanced Designs for Automated Glucose Control in Artificial Pancreas,” University of California Santa Barbara, 2016, pp. 1-152. [cited by applicant]
U.S. Notice of Allowance dated Apr. 16, 2024 in U.S. Appl. No. 17/509,670 [MEDTP031X1C1US]. [cited by applicant]
U.S. Notice of Allowance dated Apr. 24, 2024 in U.S. Appl. No. 17/509,670 [MEDTP031X1C1US]. [cited by applicant]
U.S. Notice of Allowance dated Jan. 31, 2024 in U.S. Appl. No. 16/438,407 [MEDTP014US]. [cited by applicant]
U.S. Appl. No. 18/639,434, inventors Wu D, et al., filed on Apr. 18, 2024 [MEDTP014C1US]. [cited by applicant]
Zavitsanou, et al., “Embedded Control in Wearable Medical Devices: Application to the Artificial Pancreas,” ProQuest, 2016, vol. 4(35), pp. 1-29. [cited by applicant]
CN Office Action dated Oct. 25, 2024 in CN Application No. 202080027737.6 with English translation [MEDTP014]. [cited by applicant]
EP Office Action dated Jun. 26, 2024 in EP Application No. 20724639.8 [MEDTP014]. [cited by applicant]